[HTML][HTML] Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma
AB Blair, L Zheng - Chinese clinical oncology, 2017 - ncbi.nlm.nih.gov
AB Blair, L Zheng
Chinese clinical oncology, 2017•ncbi.nlm.nih.govThe complex interaction between the immune system, the tumor and the microenvironment
in pancreatic ductal adenocarcinoma (PDA) leads to the resistance of PDA to
immunotherapy. To overcome this resistance, combination immunotherapy is being
proposed. However, rational combinations that target multiple aspects of the complex anti-
tumor immune response are warranted. Novel clinical trials will investigate and optimize the
combination immunotherapy for PDA.
in pancreatic ductal adenocarcinoma (PDA) leads to the resistance of PDA to
immunotherapy. To overcome this resistance, combination immunotherapy is being
proposed. However, rational combinations that target multiple aspects of the complex anti-
tumor immune response are warranted. Novel clinical trials will investigate and optimize the
combination immunotherapy for PDA.
Abstract
The complex interaction between the immune system, the tumor and the microenvironment in pancreatic ductal adenocarcinoma (PDA) leads to the resistance of PDA to immunotherapy. To overcome this resistance, combination immunotherapy is being proposed. However, rational combinations that target multiple aspects of the complex anti-tumor immune response are warranted. Novel clinical trials will investigate and optimize the combination immunotherapy for PDA.
ncbi.nlm.nih.gov